- Home
- ATCH vs CERO Comparison
ATCH vs CERO Comparison
Compare ATCH & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- CERO
- Stock Information
- Founded
- ATCH 2022
- CERO 2017
- Country
- ATCH United States
- CERO United States
- Employees
- ATCH N/A
- CERO N/A
- Industry
- ATCH
- CERO
- Sector
- ATCH
- CERO
- Exchange
- ATCH Nasdaq
- CERO Nasdaq
- Market Cap
- ATCH 3.4M
- CERO 3.1M
- IPO Year
- ATCH N/A
- CERO N/A
- Fundamental
- Price
- ATCH $0.42
- CERO $0.86
- Analyst Decision
- ATCH
- CERO Strong Buy
- Analyst Count
- ATCH 0
- CERO 1
- Target Price
- ATCH N/A
- CERO $11.00
- AVG Volume (30 Days)
- ATCH 653.2K
- CERO 4.6M
- Earning Date
- ATCH 05-27-2025
- CERO 05-16-2025
- Dividend Yield
- ATCH N/A
- CERO N/A
- EPS Growth
- ATCH N/A
- CERO N/A
- EPS
- ATCH 2.67
- CERO N/A
- Revenue
- ATCH N/A
- CERO N/A
- Revenue This Year
- ATCH N/A
- CERO N/A
- Revenue Next Year
- ATCH N/A
- CERO N/A
- P/E Ratio
- ATCH $0.16
- CERO N/A
- Revenue Growth
- ATCH N/A
- CERO N/A
- 52 Week Low
- ATCH $0.42
- CERO $0.53
- 52 Week High
- ATCH $84.00
- CERO $171.00
- Technical
- Relative Strength Index (RSI)
- ATCH 29.02
- CERO 50.27
- Support Level
- ATCH $0.48
- CERO $0.53
- Resistance Level
- ATCH $0.60
- CERO $1.42
- Average True Range (ATR)
- ATCH 0.07
- CERO 0.12
- MACD
- ATCH 0.07
- CERO 0.07
- Stochastic Oscillator
- ATCH 5.45
- CERO 41.19
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.